Results 21 to 30 of about 72,581 (277)

What Can Quantitative Gait Analysis Tell Us about Dementia and Its Subtypes? A Structured Review [PDF]

open access: yes, 2017
Distinguishing dementia subtypes can be difficult due to similarities in clinical presentation. There is increasing interest in discrete gait characteristics as markers to aid diagnostic algorithms in dementia.
Galna, Brook   +5 more
core   +2 more sources

Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience [PDF]

open access: yes, 2008
Background: Dementia results from heterogeneous diseases of the brain. Mixed disease forms are increasingly recognized. Methods: We performed a survey within brain banks of BrainNet Europe to estimate the proportion of mixed disease forms underlying ...
Al-Sarraj, Safa   +15 more
core   +1 more source

Diffuse Lewy body disease

open access: yesJournal of the Neurological Sciences, 2019
Diffuse Lewy body disease, also called dementia with Lewy bodies (DLB), is defined as progressive dementia and pathological Lewy bodies distributed in the central and autonomic nervous systems. The clinical features are dementia, cognitive fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD).
Yu Wei Lin, Daniel Truong
openaire   +4 more sources

Evolution of Prodromal Multiple System Atrophy from REM Sleep Behavior Disorder: A Descriptive Study

open access: yesJournal of Parkinson’s Disease, 2022
Background: Prodromal multiple system atrophy (MSA) has been characterized mainly by retrospective chart reviews. Direct observation and tracking of prodromal markers in MSA have been very limited Objective: To report the baseline characteristics and ...
Ronald B. Postuma   +3 more
doaj   +1 more source

Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population-based sample [PDF]

open access: yes, 2017
© 2017 The Authors Introduction Rapid eye movement sleep behavior disorder (RBD) is strongly associated with synucleinopathies. In 2012, we reported an increased risk of mild cognitive impairment (MCI) and Parkinson disease (PD) in cognitively normal ...
Boeve, Bradley F   +11 more
core   +2 more sources

Diffuse Lewy body disease

open access: yesNeuropathology, 1998
Diffuse Lewy body disease (DLBD) has been studied from various viewpoints and, although clinical diagnostic criteria for DLBD have been proposed, diagnosis remains difficult. DLBD has been reported to be the second most common form of dementia in the aged, following Alzheimer‐type dementia. It has, however, been clinically under‐diagnosed.
openaire   +8 more sources

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. [PDF]

open access: yes, 2019
The gold standard for a definitive diagnosis of Parkinson disease (PD) is the pathologic finding of aggregated α-synuclein into Lewy bodies and for Alzheimer disease (AD) aggregated amyloid into plaques and hyperphosphorylated tau into tangles.
Brundin, P   +26 more
core   +3 more sources

A new visual rating scale for Ioflupane imaging in Lewy body disease

open access: yesNeuroImage: Clinical, 2018
Background: Dopaminergic loss on 123I-Ioflupane brain imaging is a recognised biomarker for dementia with Lewy bodies. It is usually assessed using a visual rating scale developed for Parkinson's disease, which may not be optimal for dementia with Lewy ...
Jim J. Lloyd   +7 more
doaj   +1 more source

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. [PDF]

open access: yes, 2014
BackgroundIn dementia with Lewy bodies (DLB) abnormal interactions between α-synuclein (α-syn) and beta amyloid (Aβ) result in selective degeneration of neurons in the neocortex, limbic system and striatum.
Cartier, Anna   +9 more
core   +3 more sources

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. [PDF]

open access: yes, 2015
OBJECTIVE: The authors examined research on effects, costs, and patient and caregiver views of pharmacological management strategies for Lewy body dementia.
Cambridge, Victoria   +9 more
core   +2 more sources

Home - About - Disclaimer - Privacy